Compare Stocks → Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APVONASDAQ:AZRXNASDAQ:KMPHNASDAQ:NTECNASDAQ:SBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$0.71-7.8%$4.90$0.70▼$91.96$306K4.89212,138 shs412,322 shsAZRXAzurRx BioPharma$2.90-4.0%$4.04$3.36▼$26.30$27.05M1.51628,703 shs50,431 shsKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsNTECIntec Pharma$13.52$8.80▼$36.88$8.65M0.83543,436 shs988,300 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/A5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-7.23%-70.31%-85.69%-89.40%-99.14%AZRXAzurRx BioPharma-11.31%-15.20%-40.45%-24.48%+9.02%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%NTECIntec Pharma0.00%0.00%0.00%0.00%0.00%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics0.1147 of 5 stars0.02.00.00.01.50.01.3AZRXAzurRx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics3.00BuyN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.10N/AN/A$28.58 per share0.02AZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AKMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00NTECIntec PharmaN/AN/AN/AN/A$16.18 per shareN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$17.41MN/A0.00N/AN/AN/A-112.27%-64.39%5/9/2024 (Estimated)AZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AKMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/ANTECIntec Pharma-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/ASBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.642.64AZRXAzurRx BioPharmaN/A1.331.33KMPHZevra Therapeutics0.1410.1010.10NTECIntec PharmaN/A2.342.34SBPHSpring Bank PharmaceuticalsN/A5.115.11OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%AZRXAzurRx BioPharma6.27%KMPHZevra Therapeutics19.39%NTECIntec Pharma22.37%SBPHSpring Bank Pharmaceuticals17.17%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics1.90%AZRXAzurRx BioPharma7.30%KMPHZevra Therapeutics1.10%NTECIntec Pharma3.30%SBPHSpring Bank Pharmaceuticals12.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics40430,000420,000Not OptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableNTECIntec Pharma40898,000N/AOptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionableAZRX, KMPH, APVO, NTEC, and SBPH HeadlinesSourceHeadlineWhen will interest rates go down?thetimes.co.uk - January 31 at 12:12 PMBank of Canada expected to 'cautiously' start cutting rates in spring: Deloitte Canadaca.finance.yahoo.com - January 6 at 2:22 PMMan stabbed during street fight in Spring Bank Westhulldailymail.co.uk - September 29 at 8:36 AMWhen is the next Bank Holiday and how many are left in 2023?dailyecho.co.uk - August 13 at 4:35 AMSpring Bank fight involved two feuding families, police believehulldailymail.co.uk - August 8 at 3:14 PMCalls for more police patrols on Spring Bank after fight leaves three in hospitalhulldailymail.co.uk - August 8 at 10:14 AMSpring Bank fight: Six men and a woman held over shocking street violencehulldailymail.co.uk - August 7 at 5:57 AMThe mysterious structure on Spring Bank created to shoot out a beam of lighthulldailymail.co.uk - August 5 at 10:31 AMSyria’s Economic Outlook- Spring 2016worldbank.org - July 23 at 2:47 PMHoliday spending by bank’s customers jumped by 40% annually this springindependent.co.uk - July 17 at 9:22 AMHull's Spring Bank set for major regeneration as plans announced to make it more 'attractive'hulldailymail.co.uk - June 30 at 12:00 PMSpring 2023 Layoff Tracker: Grubhub Cuts 400 Staffforbes.com - June 14 at 8:29 PMRibchester to host 36th annual Spring Bank marketlancashiretelegraph.co.uk - June 7 at 11:53 PMThree big changes for DWP benefit payments including Spring Bank Holidaybirminghammail.co.uk - June 2 at 7:19 PMWhat shops are open this spring bank holiday Monday 2023?metro.co.uk - May 30 at 9:46 AMDWP benefit payment date changes over Spring bank holiday weekendmetro.co.uk - May 28 at 9:06 AMWhen is the the next UK Bank Holiday and how many are left in 2023?uk.news.yahoo.com - May 20 at 4:36 PMWorld Bank, IMF Spring Meetings 2023: What did FMs, central bank governors discuss?moneycontrol.com - April 23 at 3:11 PMThe three bank holidays in May as King's Coronation approachesmanchestereveningnews.co.uk - April 23 at 3:11 PMKing's Coronation bank holiday weekend could get workers 10 days off with just 4 days leavemanchestereveningnews.co.uk - April 21 at 11:06 PMIMF and World Bank Spring Meetings, NRA-ILA Leadership Forum, UN in Libya, and Morecfr.org - April 18 at 9:11 AMWorld Bank, IMF spring meetings get underway in complex economic environmentchannelnewsasia.com - April 18 at 9:11 AMSpring sales 2023: Best deals to shop this Easter bank holidayaol.co.uk - April 10 at 10:13 AMWhen are the bank holidays around the King's coronation?manchestereveningnews.co.uk - April 8 at 10:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideSoFi Presents Another Entry Opportunity for InvestorsMarch 19, 2024 7:32 AMView SoFi Presents Another Entry Opportunity for InvestorsAll Headlines Company DescriptionsAptevo TherapeuticsNASDAQ:APVOAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.AzurRx BioPharmaNASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.Zevra TherapeuticsNASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.Intec PharmaNASDAQ:NTECIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.Spring Bank PharmaceuticalsNASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.